

LUND UNIVERSITY

Mast cell-associated alveolar inflammation in patients with atopic uncontrolled asthma

Andersson, Cecilia; Bergqvist, Anders; Mori, Michiko; Mauad, Thais; Bjermer, Leif; Erjefält, Jonas

Published in: Journal of Allergy and Clinical Immunology

DOI: 10.1016/j.jaci.2011.01.022

2011

Link to publication

Citation for published version (APA): Andersson, C., Bergqvist, A., Mori, M., Mauad, T., Bjermer, L., & Erjefält, J. (2011). Mast cell-associated alveolar inflammation in patients with atopic uncontrolled asthma. Journal of Allergy and Clinical Immunology, 127(4), 905-U123. https://doi.org/10.1016/j.jaci.2011.01.022

Total number of authors: 6

General rights

Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

· Users may download and print one copy of any publication from the public portal for the purpose of private study

or research.
You may not further distribute the material or use it for any profit-making activity or commercial gain

· You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117 221 00 Lund +46 46-222 00 00

1MASTCELL-ASSOCIATEDALVEOLARINFLAMMATIONIN2PATIENTS WITH ATOPIC UNCONTROLLED ASTHMA.

3

4 Cecilia K Andersson, MSc¹, Anders Bergqvist¹, MSc¹, Michiko Mori, MSc², Thais

5 Mauad, MD, PhD³, Leif Bjermer, MD, PhD¹, and Jonas S Erjefält, PhD^{1, 2}

- ⁶ ¹Department of Respiratory Medicine and Allergology, Lund University, Lund, Sweden
- 7 ²Department of Experimental Medical Science, Lund University, Lund, Sweden
- 8 ³Department of Pathology, São Paulo University, São Paulo, Brazil
- 9

10 Corresponding author and requests for reprints should be addressed to:

- 11 Jonas Erjefält, Assoc. Prof., e-mail: jonas.erjefalt@med.lu.se
- 12 Airway Inflammation Unit, Dept. of Experimental Medical Science,
- 13 BMC D12, Lund University, SE-22184, Lund, Sweden
- 14 Phone: +46 46 222 0960, Fax: +46 46 211 3417
- 15
- 16 Sources of support: The Heart & Lung Foundation, Sweden, The Swedish Medical Research
- 17 Council, The Swedish Asthma and Allergy Associations Research Foundation, and The
- 18 Crafoord Foundation.
- 19
- **20 Word count: 3256**
- 21

22 Abstract

Background: A significant proportion of patients with asthma have persistent symptoms
despite treatment with inhaled glucocorticosteroids (ICS).

Objective: We hypothesized that in these patients the alveolar parenchyma is subjected to
 mast cell-associated alterations.

27 **Methods:** Bronchial and transbronchial biopsies from healthy controls (n=8), patients with 28 allergic rhinitis (AR) (n=8) and patients with atopic uncontrolled asthma (symptoms despite 29 treatment with ICS: mean dose: 743 μ g/day, n=14) were processed for immunohistochemical 30 identification of mast cell subtypes and mast cell expression of FccRI and surface-bound IgE.

31 Results: Whereas no difference in density of total bronchial mast cells was observed between 32 asthmatic patients and healthy controls, the total alveolar mast cell density was increased in 33 the asthmatics (p<0.01). Division into mast cell subtypes revealed that in bronchi of 34 asthmatics, MC_T numbers decreased compared to controls ($p \le 0.05$), while MC_{TC} increased 35 $(p \le 0.05)$. In the alveolar parenchyma from asthmatics an increased density was found for both 36 MC_T ($p \le 0.05$) and MC_{TC} ($p \le 0.05$). The increased alveolar mast cell densities were paralleled 37 by an increased mast cell expression of FceRI (p<0.001) compared to the controls. The 38 asthmatics also had increased numbers (p<0.001) and proportion (p<0.001) of alveolar mast 39 cells with surface-bound IgE. Similar increases in densities, FceRI expression, and surface-40 bound IgE were not seen in separate explorations of alveolar mast cells in patients with AR.

41 Conclusions: Our data suggest that patients with atopic uncontrolled asthma have an
42 increased parenchymal infiltration of MC_T and MC_{TC} populations with increased expression
43 of FccRI and surface-bound IgE compared to atopic and non-atopic controls.

45	Clinical Implications: The present mast cell alterations in the alveolar parenchyma represent
46	a novel feature of asthma that may have clinical implications and support the rational to target
47	the distal airways in uncontrolled asthmatics on ICS.

49 Capsule Summary: This study demonstrates that in asthmatic patients with persistent
50 symptoms despite conventional ICS therapy the alveolar parenchyma is infiltrated by
51 increased numbers of mast cells that have increased expression of the high-affinity receptor
52 for IgE (FceRI).

53

54

55 Key words: mast cells; asthma; FccRI; IgE; allergy; peripheral inflammation; alveolar
56 parenchyma.

58 Abbreviations

- 59 IgE: immunoglobulin E
- 60 FccRI: high affinity IgE receptor
- 61 ICS: inhaled glucocorticosteroids
- 62 GINA: global initiative for asthma
- 63 COPD: chronic obstructive pulmonary fibrosis
- 64 CF: cystic fibrosis
- 65 IPF: Idiopathic pulmonary fibrosis
- 66 AR: allergic rhinitis
- 67 ACT: asthma control test
- 68 MC_{TC}: tryptase and chymase positive mast cells (connective tissue mast cells)
- 69 MC_T: tryptase positive mast cells (mucosal mast cells)
- 70 HRP: horseradish peroxidase
- 71 DAB: 3,3' diaminobenzidine
- 72 AP: alkaline peroxidase
- 73 PD_{20} : cumulative dose of bronchoconstrictor where FEV₁ fell by 20 % or more
- 74 FEV₁: forced expiratory volume in 1 second
- 75 FVC: forced vital capacity
- 76 p.r.n: pro re nata, as needed
- 77

78 INTRODUCTION

79 Asthma is a chronic inflammatory airway disease that is characterized by a reversible airway obstruction and airway hyperreactivity^{1, 2}. Most patients have an allergic component where 80 the immunoglobulin E (IgE) plays a central role by activating key immune cells through the 81 high affinity IgE receptor, FceRI^{3, 4}. Although treatment with bronchodilators and inhaled 82 glucocorticosteroids (ICS) generally provide good control of the disease, a significant 83 proportion of the asthma patients have persistent symptoms despite conventional therapy⁵. 84 This phenomenon, referred to as uncontrolled asthma^{6,7}, represents a major challenge for 85 improved asthma control. 86

87

Despite the clinical significance of uncontrolled asthma, little is known about the inflammatory processes that evoke symptoms in this group of patients. One possibility is existence of steroid-resistant inflammatory components in the central airways⁸. Another alternative is involvement of peripheral airways^{9, 10}, which are difficult to reach by conventional inhalation therapy¹¹. The few previous studies that have explored transbronchial biopsies from asthmatics provide clear indications that both small airways and alveolar tissues may be subjected to a cellular inflammation in asthma¹²⁻¹⁴.

95

Mast cells have long been recognized as a key cell of the allergic reaction in atopic asthma, by virtue of their expression of FccRI¹⁵. They are widely present in high numbers in human peripheral airways, including the alveolar region^{10, 12, 16-18}. We recently identified a distinct mast cell population in the alveolar tissue of normal lungs¹⁹. These poorly studied alveolar mast cells, which are characterized by a low FccRI expression, comprise a large mast cell population in the human lung^{12, 19, 20}.

Increased numbers of bronchial mast cells and elevated levels of IgE have been described in 103 allergic asthma^{10, 12, 17, 21, 22}. From this, and the fact that high IgE-levels may lead to increased 104 FccRI expression on mast cells^{23, 24}, we hypothesized that patients with ICS-treated, atopic 105 106 uncontrolled asthma have a significantly altered mast cell population where the normally 107 FccRI low-expressing alveolar mast cells have acquired an FccRI-expressing phenotype. To 108 test this hypothesis mast cell densities and mast cell expression of FceRI and surface-bound 109 IgE were analyzed in bronchial and transbronchial biopsies from atopic, uncontrolled 110 asthmatics and healthy control subjects. Separate comparisons were also made with patients 111 with atopic allergic rhinitis (AR) with no concomitant asthma.

113 **METHODS**

114

115 Subjects

116 *Patients with atopic uncontrolled asthma, non-atopic and atopic control groups:*

117 The present study involved 14 non-smoking patients with uncontrolled atopic asthma 118 according to GINA guidelines and asthma control test $(ACT)^{6, 25}$. Eight healthy never-119 smoking non-atopic subjects that had negative skin prick test (SPT), were not hyper-120 responsive to metacholine, and lacked of any history of respiratory symptoms were used as 121 controls. As a separate control group, representing atopy without asthma, included 8 patients 122 with clinically confirmed AR²⁶.

123

From each of the 30 subjects, 5 central airway biopsies and 5 transbronchial biopsies (in total 300 biopsies) were collected during a study period from November 2005 to June 2010 at the Department of Respiratory Medicine, Lund University Hospital (for methodological details, see ref²⁷ and online supplement). All subjects gave their written informed consent to participate in the study, which was approved by the ethics committee in Lund (LU412-03).

129

Lungs from patients with advanced stages of non-atopic patients with chronic obstructive pulmonary disease (COPD) and cystic fibrosis were included to study the FccRI expression on alveolar mast cells in lungs subjected to a non-allergic inflammation. The clinical characterization of these patients and their matching controls, are presented in the online supplement and Table E2.

135

136 Allergy screening

137 Standardized skin prick test (SPT) (Alk Abello, Copenhagen, Denmark) was performed on all 138 subjects in all cohorts (controls, asthma, AR, COPD and CF) and was used to screen for 139 sensitization for 10 aeroallergens (birch, timothy, mugwort, cat, dog, horse, D. pteronyssinus, 140 D. farinae, Aspergillus fumigatus and Cladosporium herbarum). Atopy was defined as a 141 positive SPT (weal reaction larger or equal to histamine positive control) to one or more 142 allergens. Patients with positive SPT to pollen without any other sensitivity were classified as 143 seasonal, whereas patients with multiple sensitivities (pollen, animal, mould and/or mite) 144 were classified as perennial. For all subjects with positive SPT to seasonal pollen, bronchoscopy procedures were performed outside pollen season. 145

146

147 Tissue Processing

148 Bronchial and Transbronchial biopsies

All biopsies from uncontrolled asthmatics and 4 out of 5 bronchial and 4 out of 5 transbronchial biopsies from the healthy controls were immediately placed in 4% buffered formaldehyde, dehydrated, embedded in paraffin. Serial sections from all paraffin blocks were stained with Mayer's haematoxylin and these were used to select 2 bronchial and 2 transbronchial biopsies from each patient that had a well-preserved morphology and were without any crush, or mechanically-induced stretch artifacts. The selected biopsies were used for quantification of mast cell-related parameters.

156

The remaining biopsies from the control patients and biopsies the rhinitis cohort were immersed in periodate-lysine containing 1% paraformaldehyde (1% PLP) for 4 h at 4°C. Specimens were embedded in OCT (Tissue-Tek, Miles Laboratories, IN), and frozen. Serial cryo sections from all biopsies were generated and stored until histological assessments (see below).

162 Immunohistochemistry

All antibodies used have been extensively validated for staining of paraffin embedded human tissue sections (and cryo sections) in research and routine clinical diagnosis (Table E1). For details on immunohistochemical protocols and specificity controls^{19, 20}, see online supplement). Staining was absent in sections using isotype-matched control antibodies (Dako, Glostrup, Denmark). Staining was performed identically for all patient groups.

168

169 Double Immunohistochemical Staining of MC_{TC} and MC_T

170 A double staining protocol was used for simultaneous visualization of MC_{TC} and MC_{T} cells¹⁸⁻

171 20, 28-32. The immunohistochemistry protocol was performed using an automated

172 immunohistochemistry robot (Autostainer, Dako) with EnVision[™] G|2 Doublestain System

173 (K5361, Dako). For protocol details, see Table E1 and online supplement.

174

175 Immunohistochemical Identification of $Fc \in RI^+$ and IgE^+ Mast Cells

176 A triple staining immunofluorescence protocol^{19, 20, 33, 34} was used to simultaneously visualize

both MC_{TC} and MC_T populations together with their expression of the IgE receptor (FceRI) or

178 surface-bound IgE (see online supplement and Table E1).

179

180 Histological Analysis and Quantification

181 Quantification of Densities of Mast Cell Subtypes

High-resolution images of sections -stained for MC_{TC} and MC_T were generated through a 20x microscope lens by an automated digital slide-scanning robot (Scanscope CSTM, Aperio, Vista, CA). In bronchial biopsies the densities of MC_T and MC_{TC} was also calculated in subanatomical compartments: *epithelium, subepithelial tissue (excluding smooth muscle and glands), smooth muscle tissue and subepithelial glands*. An image analysis program 187 (ImageScope, v10.0.36.1805, Aperio) calculated the tissue area within the delineated region 188 by automatically excluding any non-tissue regions (i.e. regions without any tissue 189 components) and the proper tissue density (expressed as cells / mm^2 tissue) was calculated for 190 each mast cell subtype^{14, 19, 20, 30, 35-37}.

191

192 *Quantification of* $Fc \in RI^+$ *and* IgE^+ *Mast Cells*

After triple immunofluorescence staining, the filter setting was adjusted to reveal the tryptasepositive mast cells at 488 nm. By alternating the filter settings each tryptase-positive cell was examined for presence of chymase (647 nm) as well as expression of FccRI α or surfacebound IgE (555 nm). The density of mast cells expressing FccRI and IgE was calculated by multiply the percentage of MC^{Fc,RI+} or MC^{IgE+} with the total mast cell density in the same tissue region (for further details and quantification on COPD and CF, see ref ¹⁸ and online supplement).

200

201 Statistical Analysis

Data were analyzed statistically on mean values from each patient, using Mann-Whitney rank sum test for comparison between two groups (disease vs. control) using GraphPad Prism v. 5 (GraphPad Software Inc., La Jolla, CA). For all outcomes, a p-value ≤ 0.05 was considered significant (* denotes p ≤ 0.05 , ** p < 0.01 and *** < 0.001).

- 206
- 207
- 208

209 RESULTS

210

211 Clinical Characteristics

An overview of the patient characteristics is presented in Table 1.

213 Uncontrolled asthma: The 14 asthma patients included in the study had symptomatic 214 uncontrolled asthma (ACT score ranging from 11 to 21). All were atopic (i.e. positive SPT), 215 and all but one had rhinitis. All asthma patients were treated with inhaled glucocorticosteroids 216 (Budesonid) and inhaled bronchodilators (Table 1). Two patients were treated with 217 leukotriene-receptor antagonists and 3 had nasal corticosteroids and anti-histamines p.r.n. In 218 addition, 1 patient was treated for hypertension (losartan potassium/hydrochlorothiazide), 2 219 for gastritis (omeprazole) and 1 with vitamin B substitute. None of the patients were treated 220 with anti-IgE therapy. Two patients had seasonal and 12 had perennial allergy. AR: The 8 221 patients with AR with no concomitant asthma all had positive SPT and were not hyper-222 responsive to metacholine (PD20 > 2000 μ g). None of the AR patients were treated with 223 inhaled bronchodilators or glucocorticosteroids. Two had nasal corticosteroids and 4 had anti-224 histamines p.r.n. One patient had seasonal and 7 had perennial allergy. *Healthy controls:* All 225 healthy controls were without any respiratory symptoms, had normal lung function, and 226 negative SPT and metacholine challenge test (PD20 > 2000 μ g). FEV₁ % predicted was lower 227 in patients with asthma (81 [63-108] FEV₁ % pred.) compared to healthy controls (98 [72-228 116] FEV₁ % pred., p = 0.03) and patients with rhinitis (107 [96-138] FEV₁ % pred., p =229 0.001). No difference in FEV₁ % pred. was found between controls and rhinitis (p = 0.3). In addition, 5 CF and 10 COPD patients were investigated^{19, 20} (for patient and protocol details, 230 231 see online supplement).

233 Characterization of Mast Cell Phenotypes in Uncontrolled Asthma and Healthy234 Controls

235 Densities of MC_T and MC_{TC} Populations

236 In central airways, the total tissue density of mast cells did not differ between patients with 237 uncontrolled asthma and healthy control subjects (Table 2). In contrast, the alveolar 238 parenchyma displayed increased numbers of mast cells in patients with uncontrolled asthma 239 compared to healthy controls (Table 2). The unaltered total mast cell numbers in central 240 airways in uncontrolled asthma was a result of a decrease in MC_T numbers combined with an 241 increase in MC_{TC} numbers compared to healthy controls (Table 2 and Figure 1). The 242 significant increase in total alveolar mast cell numbers in uncontrolled asthmatics was due to 243 an increase in both MC_T cells and MC_{TC} numbers compared to healthy controls (Table 2 and 244 Figure 1).

245

246 Microlocalization of Mast Cell Subtypes in Central Airways

The highest density of mast cells was found in the lamina propria for both control subjects and asthmatics. No difference in the distribution of mast cells was found for the MC_T subclass in asthmatics compared to controls (Table E3). The MC_{TC} density increased in the smooth muscle layer in asthmatics (7.1 [0-25] mast cells per mm²) compared to controls (1.0 [0-5] mast cells per mm², p = 0.01) (Table E3).

252

253 Expression of FceRIa and IgE on Bronchial and Alveolar Mast Cells

Both Fc ϵ RI α and IgE immunoreactivity displayed a characteristic membrane staining in triple-stained immunofluorescence sections. As previously shown^{12, 19, 38}, the proportion of mast cell expressing Fc ϵ RI α was high in central airways in healthy subjects, and no significant difference in expression to uncontrolled asthmatics was observed (Figure 2A and Table 2). The mast cell expression of FceRI α did not differ between controls and asthmatics, neither for MC_T (p = 0.4) nor for the MC_{TC} subtype (p = 0.5). In contrast, in the alveolar parenchyma, the mast cell expression of FceRI α was low in healthy controls and significantly higher in uncontrolled asthma (Figure 2B, C-D and Table 2). The increased FceRI α expression in uncontrolled asthma was further confirmed using a computerized image analysis approach was used to calculate the area of FceRI α immunoreactivity on individual mast cells (see online supplement).

265

In central airways, the proportion of IgE^+ mast cells was low in healthy controls and significantly increased in uncontrolled asthmatics (Figure 2E and Table 2). Also in the alveolar parenchyma, the proportion of IgE^+ mast cells was low in controls and significantly increased in the alveolar parenchyma (Figure 2F, G-H and Table 2). As for the expression of FceRI α , no difference in mast cell-bound IgE was found between MC_T and MC_{TC} subclasses, neither in central airways (controls: p = 0.5, asthma: p = 0.2) nor in alveolar parenchyma (controls: p = 0.4, asthma: p = 0.1).

273

In alveolar parenchyma, the tissue density of FcɛRI α positive mast cells was increased in uncontrolled asthmatics (132 [9-591] MC^{Fc_iRI_a+/mm²}) compared to controls (1.5 [0-27] MC^{Fc_iRI_a+/mm², p = 0.0003) (Figure 3A). Also an increase in the density of mast cells positive for surface-bound IgE was found in the asthmatics (133 [8-591] MC^{IgE+}/mm²) compared to controls (0 [0-3] MC^{IgE+}/mm², p = 0.0001) (Figure 3B).}

279

280 FcεRIα and IgE expression on Alveolar Mast Cells in AR and Non-Allergic
281 Inflammatory Diseases

282 Allergic Rhinitis

In AR, no significant change in total mast cell numbers or the density of MC_T and MC_{TC} was found in central airways or in alveolar parenchyma compared to healthy controls (Table 2). No increase in the proportion of mast cells expressing the FccRI α could be found in central airways or in the alveolar parenchyma in patients with AR compared to controls (Table 2). No significant increase in the proportion of mast cells with surface bound IgE was found in central airways. However, an increase in the proportion of mast cells with surface bound IgE was found in alveolar parenchyma in patients with AR compared to controls (Table 2).

290

291 Non-Allergic Lung Diseases: Comparison to COPD and CF

The Fc ϵ RI α expression was high in central airways in controls compared to the same compartment in COPD and CF. In alveolar parenchyma, the mast cell Fc ϵ RI α expression was low in controls; no significant change was found in COPD and CF patients (see online supplement).

297 **DISCUSSION**

298

Accumulated evidence from physiological studies and tissue explorations suggest that inflammatory processes in the distal airways contribute to asthma pathogenesis³⁹. The present study advances our insight about the nature of this inflammation by identifying an alveolar infiltration of altered MC_T and MC_{TC} populations as a novel histopathological feature.

303

The present study took advantage of our possibility to obtain bronchial as well as transbronchial biopsies, not only from patients with uncontrolled asthma, but also from healthy control subjects. Thus, our approach allowed the first exploration of how mast cells in both bronchial and alveolar compartments in uncontrolled asthmatics differ from healthy base-line conditions.

309

310 The discovery of increased FceRI-expression on alveolar mast cells in uncontrolled asthma 311 represents a major finding in this study. Mast cells in most types of tissues, especially those facing the external environment, have a high basal expression of FceRI¹⁵. The alveolar mast 312 cells, however, have under healthy conditions a very low FceRI expression¹⁹. In this study the 313 314 number of FceRI expressing mast cells in the alveolar parenchyma in uncontrolled asthma 315 was 40-fold higher than what could be observed in healthy controls. Furthermore, this was 316 associated with an equally robust (500-fold) increase in numbers of mast cells with surface-317 bound IgE, suggesting that the alveolar mast cells in uncontrolled asthma have acquired a 318 phenotype fully capable to classical IgE-mediated activation. Importantly, this feature seems 319 to be specific to asthma since we by same staining techniques could not detect similar 320 changes in patients with severe non-allergic alveolar inflammation (end-stage CF, or COPD) 321 as well as atopic patients with AR.

323 The low expression of $Fc \in RI\alpha$ on alveolar mast cells in AR, present in our study, indicates 324 that atopy per se does not cause the altered alveolar mast cell phenotypes found in 325 uncontrolled asthma. It should however be noted that the situation may be different in AR patients during episodes of increased allergen exposure. Although we could not find increased 326 327 FceRI expression in central airways, previous studies have reported increased numbers of bronchial FceRI⁺ mast cells in atopic, non-asthmatic subjects³⁸. The vast majority of patients 328 with asthma have rhinitis⁴² and rhinitis, especially at severe stages, is a major risk factor for 329 developing asthma⁴³⁻⁴⁵. Hence, in future studies it seems important to explore the FccRI 330 331 expression on alveolar mast cells in high-risk rhinitis patients and newly diagnosed asthma 332 patients with rhinitis. If high FccRI and IgE-expressing alveolar mast cells are present in 333 additional asthma cohorts needs to be further investigated. Furthermore, we could not detect 334 similar changes in other airway diseases characterized by extensive alveolar inflammation 335 and/or remodeling like COPD and cystic fibrosis, despite a rich occurrence of alveolar mast 336 cells in these diseases. It should however be noted that CF and COPD differs from the 337 uncontrolled asthmatic group, not only in pathological features but also in treatment. Despite 338 their medication, these patients have a significant remaining inflammatory response in the 339 alveolar parenchyma. In this inflammation the alveolar mast cells have a low expression of 340 the IgER.

341

Although most of the inhaled allergens are deposited in the conducting airways, common allergens may well be transported by respirable particles all the way to the alveolar region⁴⁶⁻ ⁴⁸. For patients sensitized to systemic allergens, the presence of FccRI⁺ mast cells in the alveolar parenchyma could theoretically contribute to the increased risk of anaphylaxis associated with asthma⁴⁹. If occurring, an IgE-driven allergic inflammation in the alveolar parenchyma is likely to have pathophysiological implications. Several mast cell mediators
have pro-fibrotic and matrix-modulating properties and may thus contribute to the structural
alterations that recently have been observed in alveolar tissues from asthmatics²⁷.

350

In 2002, Brightling et al¹⁷ showed that the density of mast cells in the airway smooth muscle 351 352 layer increased in asthmatic subjects. This phenomenon was also found in the present study. where an increased density of MC_{TC} cells, but not MC_{T} , was found in the bronchial smooth 353 354 muscle layer of uncontrolled asthmatics compared to the same compartment in healthy 355 controls. Given that this mast cell subtype is thought to be steroid insensitive, and that several 356 mast cell mediators have the ability to cause airway bronchoconstriction, hyperresponsiveness 357 and remodeling, this finding supports the proposed pathophysiological effects of smooth muscle-associated mast cells in asthma^{54, 55}. 358

359

In this study, we found no direct correlations between mast cell parameters and lung function values within the uncontrolled asthma cohort in this study (see online supplement). However, the number of patients was small and previous studies have shown that conventional lung functional parameters might not accurately represent distal lung inflammation⁵⁶. Indeed, it has been demonstrated that measurements of thoracic gas volume and total lung capacity better represents peripheral inflammation, and that these parameters correlate to e.g. distal eosinophilic inflammation in patients with nocturnal asthma³⁷.

367

368 In support of a beneficial effect of the ongoing treatment with ICS, the MC_T population 369 decreased in central airways of asthmatics, while the MC_{TC} numbers increased. As steroids 370 have previously been showed to reduce mast cell numbers in central airways and to mainly 371 affect the MC_T population⁵⁷, this observation implies an effect of ICS on mast cells in the bronchi. In contrast, both MC_T and MC_{TC} subpopulations increased significantly in the less steroid-exposed alveolar parenchyma, which indicates that alveolar mast cell populations are not well targeted by conventional ICS therapy.

375

376 Our data support the notion that patients who do not respond to conventional ICS therapy may 377 have a peripheral airway inflammation and should thus benefit from treatment strategies with improved targeting of the distal lung^{11, 58}. ICS, which are the foundation treatment of choice 378 for asthma patients^{6, 59, 60}, were originally developed to primarily treat the central airways. 379 380 Anti-IgE therapy (Omalizumab; Xolair®) was developed on the basis of the proposed IgEdriven allergic inflammation in the conducting airways⁶³⁻⁶⁵. Omalizumab down-regulate both 381 IgE and FceRI-bearing mast cells in asthmatic bronchi^{3, 66}. Future studies are now needed to 382 383 investigate if anti-IgE therapy yields similar effects in the alveolar compartment.

384

In summary, this study has demonstrated that atopic asthma patients with persistent symptoms despite conventional ICS therapy have increased MC_T and MC_{TC} populations in the alveolar parenchyma. These expanded populations are characterized by markedly elevated expression of FccRI and surface-bound IgE. Apart from advancing the concept of a distal airway inflammation in asthma, this observation provides important indications regarding how to improve treatment strategies for uncontrolled asthma.

392 ACKNOWLEDGEMENTS

- 393 We thank Karin Jansner and Britt-Marie Nilsson for skillful technical assistance with tissue
- 394 processing and immunohistochemical staining.

396 REFERENCES

397 398

1. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease.

- 399 Nat Rev Immunol 2008; 8:183-92.
- 400 2. Busse WW, Lemanske RF, Jr. Asthma. N Engl J Med 2001; 344:350-62.
- 401 3. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-
- 402 inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
- 403 J Allergy Clin Immunol 2005; 115:459-65.
- 404 4. Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the
- 405 development of asthma. Nature 1999; 402:B12-7.
- 406 5. Holgate ST. Novel targets of therapy in asthma. Curr Opin Pulm Med 2009;
 407 15:63-71.
- 408 6. Global Initiative for asthma. GINA Report, Global Strategy for Asthma
 409 Management and Prevention. www.ginasthma.com. 2006.
- 410 7. Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, et al. Asthma
- 411 control in Europe: a real-world evaluation based on an international population-based study. J
- 412 Allergy Clin Immunol 2007; 120:1360-7.
- 8. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases.
- 414 Lancet 2009; 373:1905-17.
- 415 9. de Magalhaes Simoes S, dos Santos MA, da Silva Oliveira M, Fontes ES,
- 416 Fernezlian S, Garippo AL, et al. Inflammatory cell mapping of the respiratory tract in fatal
- 417 asthma. Clin Exp Allergy 2005; 35:602-11.
- 418 10. Elliot JG, Abramson MJ, Drummer OH, Walters EH, James AL. Time to death
- and mast cell degranulation in fatal asthma. Respirology 2009; 14:808-13.
- 420 11. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J
- 421 Allergy Clin Immunol 2002; 109:S447-60.

422	12.	Balzar S, Strand M, Rhodes D, Wenzel SE. IgE expression pattern in lung:
423	relation to s	ystemic IgE and asthma phenotypes. J Allergy Clin Immunol 2007; 119:855-62.
424	13.	Bergeron C, Hauber HP, Gotfried M, Newman K, Dhanda R, Servi RJ, et al.
425	Evidence of	remodeling in peripheral airways of patients with mild to moderate asthma: effect
426	of hydrofluc	proalkane-flunisolide. J Allergy Clin Immunol 2005; 116:983-9.
427	14.	Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue
428	inflammatio	on in asthma. Am J Respir Crit Care Med 1996; 154:1505-10.
429	15.	Bradding P, Walls AF, Holgate ST. The role of the mast cell in the
430	pathophysio	logy of asthma. J Allergy Clin Immunol 2006; 117:1277-84.
431	16.	Craig SS, DeBlois G, Schwartz LB. Mast cells in human keloid, small intestine,
432	and lung by	an immunoperoxidase technique using a murine monoclonal antibody against
433	tryptase. An	n J Pathol 1986; 124:427-35.
434	17.	Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID.
435	Mast-cell in	filtration of airway smooth muscle in asthma. N Engl J Med 2002; 346:1699-705.
436	18.	Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites.
437	Fluorescent	determination of avidin binding and immunofluorescent determination of
438	chymase, try	yptase, and carboxypeptidase content. Pathol Res Pract 1993; 189:156-62.
439	19.	Andersson CK, Mori M, Bjermer L, Lofdahl CG, Erjefalt JS. Novel site-specific
440	mast cell sul	bpopulations in the human lung. Thorax 2009; 64:297-305.
441	20.	Andersson CK, Mori M, Bjermer L, Lofdahl CG, Erjefalt JS. Alterations in lung
442	mast cell po	pulations in patients with chronic obstructive pulmonary disease. Am J Respir
443	Crit Care M	ed 2010; 181:206-17.
444	21.	Brown JL, Behndig AF, Sekerel BE, Pourazar J, Blomberg A, Kelly FJ, et al.
445	Lower airwa	ays inflammation in allergic rhinitics: a comparison with asthmatics and normal
446	controls. Cli	in Exp Allergy 2007; 37:688-95.

den Otter I, Silva LF, Carvalho AL, Pires-Neto RC, Annoni R, Ferreira DS, et
al. High-affinity immunoglobulin E receptor expression is increased in large and small
airways in fatal asthma. Clin Exp Allergy 2010; 40:1473-81.

450 23. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 2008;
451 8:205-17.

452 24. Smurthwaite L, Walker SN, Wilson DR, Birch DS, Merrett TG, Durham SR, et
453 al. Persistent IgE synthesis in the nasal mucosa of hay fever patients. Eur J Immunol 2001;
454 31:3422-31.

Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, et al. Asthma
Control Test: reliability, validity, and responsiveness in patients not previously followed by

457 asthma specialists. J Allergy Clin Immunol 2006; 117:549-56.

458 26. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al.

459 Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the

460 World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 Suppl 86:8-160.

461 27. Nihlberg K, Andersson-Sjoland A, Tufvesson E, Erjefalt JS, Bjermer L,

Westergren-Thorsson G. Altered matrix production in the distal airways of individuals withasthma. Thorax 2010; 65:670-6.

464 28. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of
465 human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A
466 1986; 83:4464-8.

467 29. Irani AM, Nilsson G, Miettinen U, Craig SS, Ashman LK, Ishizaka T, et al.
468 Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed
469 human fetal liver cells. Blood 1992; 80:3009-21.

470 30. KleinJan A, McEuen AR, Dijkstra MD, Buckley MG, Walls AF, Fokkens WJ.

471 Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of

- 472 patients with hay fever after local allergen provocation. J Allergy Clin Immunol 2000;473 106:677-86.
- 474 31. Weidner N, Austen KF. Ultrastructural and immunohistochemical
- 475 characterization of normal mast cells at multiple body sites. J Invest Dermatol 1991; 96:26S-
- 476 30S; discussion S-1S, 60S-5S.
- 477 32. Mori A, Zhai YL, Toki T, Nikaido T, Fujii S. Distribution and heterogeneity of
 478 mast cells in the human uterus. Hum Reprod 1997; 12:368-72.
- 479 33. Brown JK, Pemberton AD, Wright SH, Miller HR. Primary antibody-Fab
- 480 fragment complexes: a flexible alternative to traditional direct and indirect immunolabeling
- techniques. J Histochem Cytochem 2004; 52:1219-30.
- 482 34. Toivonen R, Mayranpaa MI, Kovanen PT, Savontaus M. Dilated
- 483 cardiomyopathy alters the expression patterns of CAR and other adenoviral receptors in
- 484 human heart. Histochem Cell Biol 2010; 133:349-57.
- 35. Balzar S, Chu HW, Strand M, Wenzel S. Relationship of small airway chymasepositive mast cells and lung function in severe asthma. Am J Respir Crit Care Med 2005;
- **487** 171:431-9.
- 488 36. Balzar S, Wenzel SE, Chu HW. Transbronchial biopsy as a tool to evaluate
 489 small airways in asthma. Eur Respir J 2002; 20:254-9.
- 490 37. Sutherland ER, Martin RJ, Bowler RP, Zhang Y, Rex MD, Kraft M. Physiologic
- 491 correlates of distal lung inflammation in asthma. J Allergy Clin Immunol 2004; 113:1046-50.
- 492 38. Humbert M, Grant JA, Taborda-Barata L, Durham SR, Pfister R, Menz G, et al.
- 493 High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and
- 494 nonatopic asthma. Am J Respir Crit Care Med 1996; 153:1931-7.
- 495 39. Gelfand EW, Kraft M. The importance and features of the distal airways in
- 496 children and adults. J Allergy Clin Immunol 2009; 124:S84-7.

497	40.	Csaba G, Kovacs P, Pallinger E. Gender differences in the histamine and
498	serotonin c	ontent of blood, peritoneal and thymic cells: a comparison with mast cells. Cell
499	Biol Int 20	03; 27:387-9.

500 41. Dunlop SP, Jenkins D, Spiller RC. Age-related decline in rectal mucosal

501 lymphocytes and mast cells. Eur J Gastroenterol Hepatol 2004; 16:1011-5.

502 42. Greisner WA, 3rd, Settipane RJ, Settipane GA. Co-existence of asthma and

allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc 1998;

504 19:185-8.

505 43. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk
506 factor for adult-onset asthma. J Allergy Clin Immunol 2002; 109:419-25.

507 44. Linneberg A, Henrik Nielsen N, Frolund L, Madsen F, Dirksen A, Jorgensen T.

508 The link between allergic rhinitis and allergic asthma: a prospective population-based study.

509 The Copenhagen Allergy Study. Allergy 2002; 57:1048-52.

510 45. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing
511 asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994;
512 15:21-5.

513 46. Custovic A, Woodcock H, Craven M, Hassall R, Hadley E, Simpson A, et al.

514 Dust mite allergens are carried on not only large particles. Pediatr Allergy Immunol 1999;

515 10:258-60.

516 47. Taylor PE, Flagan RC, Miguel AG, Valenta R, Glovsky MM. Birch pollen

rupture and the release of aerosols of respirable allergens. Clin Exp Allergy 2004; 34:1591-6.

518 48. Taylor PE, Flagan RC, Valenta R, Glovsky MM. Release of allergens as

respirable aerosols: A link between grass pollen and asthma. J Allergy Clin Immunol 2002;

520 109:51-6.

- 521 49. Gonzalez-Perez A, Aponte Z, Vidaurre CF, Rodriguez LA. Anaphylaxis
- 522 epidemiology in patients with and patients without asthma: a United Kingdom database
- 523 review. J Allergy Clin Immunol 2010; 125:1098-104 e1.
- 524 50. Hakim-Rad K, Metz M, Maurer M. Mast cells: makers and breakers of allergic
 525 inflammation. Curr Opin Allergy Clin Immunol 2009; 9:427-30.
- 526 51. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol
 527 2008; 9:1215-23.
- 528 52. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation.
 529 Nature 2008; 454:445-54.
- 530 53. Fischer M, Harvima IT, Carvalho RF, Moller C, Naukkarinen A, Enblad G, et
- al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates
- degranulation-independent chemokine secretion. J Clin Invest 2006; 116:2748-56.
- 533 54. Berger P, Laurent F, Begueret H, Perot V, Rouiller R, Raherison C, et al.
- 534 Structure and function of small airways in smokers: relationship between air trapping at CT
- and airway inflammation. Radiology 2003; 228:85-94.
- 536 55. Berger P, Girodet PO, Begueret H, Ousova O, Perng DW, Marthan R, et al.
- 537 Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast
- 538 cell chemotaxis. FASEB J 2003; 17:2139-41.
- 539 56. Wagner EM, Liu MC, Weinmann GG, Permutt S, Bleecker ER. Peripheral lung
 resistance in normal and asthmatic subjects. Am Rev Respir Dis 1990; 141:584-8.
- 541 57. Bentley AM, Hamid Q, Robinson DS, Schotman E, Meng Q, Assoufi B, et al.
- 542 Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-
- only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene
- expression within the bronchial mucosa. Am J Respir Crit Care Med 1996; 153:551-6.

- 545 58. Hamid Q, Tulic MK. New insights into the pathophysiology of the small
 546 airways in asthma. Ann Thorac Med 2007; 2:28-33.
- 547 59. FitzGerald JM, Shahidi N. Achieving asthma control in patients with moderate
 548 disease. J Allergy Clin Immunol 2010; 125:307-11.
- 549 60. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332:868-75.
- 550 61. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting
- response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;
- 552 125:1378-86.
- 553 62. Jabara HH, Ahern DJ, Vercelli D, Geha RS. Hydrocortisone and IL-4 induce
- IgE isotype switching in human B cells. J Immunol 1991; 147:1557-60.
- 555 63. Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on
- markers of inflammation in patients with allergic asthma. Allergy 2009; 64:1728-36.
- 55764.Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma.
- 558 Am J Respir Crit Care Med 2001; 164:S12-7.
- 559 65. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006;560 354:2689-95.
- 561 66. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The
- 562 effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and
- 563 emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-8.
- 564
- 565
- 566

Subject	Asthma / Controls	Gender (M/F)	Age (yrs)	FEV1 (L)	FEV ₁ % of pred.	PD20 (μg)	Atopy (y/n)	Rhinitis (y/n)	ICS/day (µg)	ACT score	Smoking (y/n)
1	control	М	29	5.11	116.4	>2000	n	n	0	N/A	n
2	control	F	23	3.68	95.4	>2000	n	n	0	N/A	n
3	control	М	39	4.91	109.8	>2000	n	n	0	N/A	n
4	control	М	23	5.38	113.5	>2000	n	n	0	N/A	n
5	control	F	23	3.71	100.7	>2000	n	n	0	N/A	n
6	control	F	22	2.38	72.1	>2000	n	n	0	N/A	n
7	control	F	23	3.53	95.1	>2000	n	n	0	N/A	n
8	control	F	21	3.25	89.4	>2000	n	n	0	N/A	n
9	rhinitis	М	22	3.98	108.7	>2000	y (p)	у	0^{a}	N/A	n
10	rhinitis	F	25	2.98	96.3	>2000	y (p)	у	0	N/A	n
11	rhinitis	F	36	3.21	103.8	>2000	y (p)	у	0	N/A	n
12	rhinitis	М	59	3.01	138.0	>2000	y (p)	у	0^{a}	N/A	n
13	rhinitis	F	24	3.42	96.0	>2000	y (p)	у	0	N/A	n
14	rhinitis	F	24	3.21	105.0	>2000	y (p)	у	0	N/A	n
15	rhinitis	М	29	4.69	114.6	>2000	y (s)	у	0	N/A	n^b
16	rhinitis	F	31	3.68	109.3	>2000	y (p)	у	0	N/A	n
17	asthma	М	45	4.25	104.2	243.4	y (p)	У	400	13	n
18	asthma	М	59	3.17	81.0	672.0	y (p)	у	800	19	n
19	asthma	М	27	3.86	81.7	>2000	y (p)	n	800	20	n
20	asthma	М	22	3.58	79.9	251.5	y (p)	у	400	21	n
21	asthma	М	58	2.80	63.3	68.0	y (p)	у	400	13	n
22	asthma	М	30	4.01	90.1	1620.0	y (p)	у	800	18	n
23	asthma	F	50	2.14	74.7	69.3	y (p)	у	800	16	n
24	asthma	F	24	2.35	72.5	381.9	y (s)	У	1200	20	n
25	asthma	F	50	2.07	72.3	138.2	y (p)	У	800	17	n ^c
26	asthma	F	52	2.37	81.5	279.1	y (p)	у	800	14	n
27	asthma	М	38	4.64	108.0	541.0	y (p)	У	1200	17	n
28	asthma	М	37	4.14	96.0	500.0	y (p)	у	400	18	n^d
29	asthma	М	25	3.35	73.3	59.5	y (p)	у	800	18	n
30	asthma	F	42	2.55	81.8	326.0	y (s)	у	800	11	n

TABLE 1. SUBJECT CHARACTERISTICS FOR UNCONTROLLED ASTHMA, AR AND HEALTHY CONTROLS


 $M = male, F = female, FEV_1 = forced expiratory volume in 1 second, PD20 = provocative dose (metacholine) producing a fall in FEV_1 of 20 %, s = seasonal, p = perennial, ICS = Inhaled glucocorticosteroid, ACT = asthma control test, y = yes, n = no, ^a nasal corticosteroid p.r.n, ^b ex-smoker since 2003, ^c ex-smoker since 1985, ^d ex-smoker since 2001$

TABLE 2. MAST CELL DENSITIES AND EXPRESSION OF FCERI AND MAST CELL BOUND IGE IN PATIENTS WITH UNCONTROLLED ASTHMA AND AR

		(Central Airways		Alveolar Parenchyma			
Uncontrolled As Density (per mm ²)		Controls ^a (n = 8)	Uncontrolled asthma (n=14)	p-value	Controls (n = 8)	Uncontrolled asthma (n=14)	p-value	
	Total	69 (16-185)	40 (12-109)	0.2	53 (0-241)	210 (59-591)	0.006	
	MC _T	60 (11-179)	19 (0-69)	0.05	33 (0-239)	178 (22-456)	0.01	
	MC_{TC}	10 (0-24)	24 (5-83)	0.05	12 (0-31)	38 (5-299)	0.04	
Expression (%)	FceRI	69 (43–100)	86 (50-100)	0.1	3 (0-11)	81 (8-100)	0.0002	
	IgE	31 (11-75)	91 (30-100)	0.003	0 (0-12)	73 (13-100)	0.0001	
AR								
Density (per mm ²)	1	Controls ^b	AR		Controls	AR		
		(n=8)	(n=8)	p-value	(n=8)	(n=8)	p-value	
	Total	79 (31-155)	83 (65-319)	0.7	61 (0-179)	79 (32-186)	0.2	
	MC _T	72 (10-155)	66 (14-265)	1.0	46 (0-149)	64 (0-180)	0.6	
	MC _{TC}	15 (0-28)	21 (8-61)	0.3	10 (0-30)	18 (6-68)	0.2	
Expression (%)	FceRI	73 (40-100)	76 (40-100)	0.6	0 (0-29)	0 (0-19)	0.8	
	IgE	13 (0-50)	30 (0-51)	0.2	0 (0-17)	11 (0-37)	0.02	


Data presented as median (range). ^a Paraformaldehyde fixated paraffin embedded control tissue, ^b PLP fixated cryo control tissue. n = number of patients in the group. A mean value per each patient was calculated from 2 bronchial and 2 transbronchial biopsies, respectively. The difference between the control group and disease group were then calculated using Mann-Whitney test. Result is considered significant for $p \le 0.05$.

569




571 572

Figure 1. MC_T and MC_{TC} in central airways (A, C) and alveolar parenchyma (B, D) in uncontrolled asthma compared to healthy controls. E (central airways) and F (alveolar) show representative micrographs from asthmatic patients, double stained for MC_T and MC_{TC} . Scale bar: E-F = 100 µm. Inset in (E) represents a close-up image (600×) of neighboring MC_{TC} and MC_T cells. Horizontal bars indicates median value.



579

Figure 2. Mast cell expression (%) of Fc ϵ RI (A-B), panel C-D show representative micrographs of Fc ϵ RI⁺ mast cells in alveolar parenchyma from controls (C) and asthmatic patients (D). E-F show mast cell bound IgE (%), panel G-H show representative micrographs of IgE⁺ mast cells in alveolar parenchyma from controls (G) and asthmatic patients (H). Scale bar: C-D, G = 50 µm and H = 25 µm. Insets represents image (600×) of mast cells double positive for tryptase and Fc ϵ RI α or IgE. Horizontal bars indicates median value.



587

588 Figure 3. Density of mast cells expressing FccRIa (A) and mast cell bound IgE (B) in

alveolar parenchyma in uncontrolled asthma compared to healthy controls. Data are presented

590 as box and whiskers.